Aardvark Therapeutics Updates Corporate Presentation with Strong Obesity Pipeline Data and Phase 2 Trial Progress

summarizeSummary

Aardvark Therapeutics updated its corporate presentation, revealing strong preclinical data for its obesity drug ARD-201 and confirming the advancement of two Phase 2 obesity trials, alongside an ongoing Phase 3 trial for Prader-Willi Syndrome.

check_boxKey Events

• Strong Preclinical Obesity Data for ARD-201

  Preclinical studies for ARD-201 in a diet-induced obesity mouse model showed approximately 19% weight loss in 30 days, prevention of weight regain post-GLP-1RA withdrawal, and enhanced efficacy when combined with GLP-1RA therapy.

• Advancement of Obesity Pipeline

  The company initiated a Phase 2 POWER trial for weight maintenance in patients post-GLP-1RA induced weight loss and expects to initiate a Phase 2 STRENGTH trial for weight loss in the first half of 2026.

• Ongoing Phase 3 Trial for Prader-Willi Syndrome

  The Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome (hyperphagia) is currently enrolling, with topline data expected in Q3 2026.

• Extended Financial Runway

  Aardvark Therapeutics announced its balance sheet is funded into 2027, providing capital for ongoing and planned clinical developments.

auto_awesomeAnalysis

Aardvark Therapeutics' updated corporate presentation highlights significant progress in its obesity pipeline, particularly with ARD-201. The preclinical data demonstrating substantial weight loss, prevention of weight regain, and enhanced GLP-1RA efficacy positions ARD-201 as a promising candidate in a highly competitive and lucrative market. The initiation of two Phase 2 trials for obesity, alongside the ongoing Phase 3 trial for Prader-Willi Syndrome, indicates a robust development strategy. The extended financial runway into 2027 provides stability for these programs.